7. Survival analysis
The median follow-up duration was 38.7 months (range: 2.7-317.6 months). 41 (57.7%) patients died during follow-up. 5-year OS for the entire cohort was 52.9% (Figure S1). Stage-specific 5-year OS were as follows: stage I—60.7%, stage II-IV—27.8% (P=0.001; Figure S2). Patients experienced first recurrence after initial diagnoses within 12 months had a worse 5-year OS than those after 12 months (17.0% vs 69.1%, P<0.001, Figure 1A). 5-year OS for the SCS and non-SCS subgroup was 62.0% and 28.0%, respectively (P<0.001; Figure S3). Patients who recurred at isolated site associated had a better survival (5-year OS: 73.5% vs 44.0%, P=0.045; Figure S4). Patients who developed recurrence in multiple locations had a significantly worse survival (5-year OS: 58.4% vs 34.7% P=0.039, Figure 2).
Of the 52 patients undergoing SCS, patients experienced first recurrence after initial diagnoses within 12 months had a worse 5-year OS than those after 12 months (28.5% vs 72.8%, P=0.001, Figure 1B). Patients with residual tumors after cytoreductive surgery had a tendency towards a worse survival than those without (5-year OS: 20.0% vs 67.7%, P=0.082; Figure S5). Patients who received non-genital organ surgeries had a non-significantly worse survival than those who did not receive (5-year OS: 51.5% vs 69.8%, P=0.057; Figure S6). And patients with lung-only recurrence (n=10) had a tendency towards better 5-year OS than those without (n=42) (77.8%% vs 57.8%, P=0.938; Figure S7).
Multivariate analysis showed time to fist recurrence within 12 months (HR=4.60, 95% CI: 1.49-14.4, P = 0.008, Table 5) was an independent predictor of decreased 5-year OS after adjusted time to fist recurrence, diameter of largest mass found at SCS, isolated site recurrence, multiple locations, non-genital organ surgeries, residual tumor, adjuvant chemotherapy.